Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M

Twist Bioscience Corp

2024-FY EPS reported -$3.60 revenue$312,974,000

FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.
Gross margin improved to 45.1% in Q4FY24 (from 36.6%); net loss narrowed to $34.7M ($0.59/share) from $46.2M ($0.81/share).
FY2025 guidance: revenue $367M-$377M; targeting 50% gross margin by Q4FY25.
Adjusted EBITDA improved to -$93.5M FY2024 vs -$147.3M FY2023; cash $276.4M at year-end.
Entered $15M royalty purchase agreement with XOMA; launched FlexPrep NGS kit with proprietary enzyme.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.